Agree, with the qualification that the approval for other cancers might come more quickly when considering the urgent need and the safety seen with dcvax unlike a lot of other cancer treatments.
The success against GBM that we expect and the promising results of the smaller trials applying dcvax against other cancers, and the successful treatment of that woman who told her story of having a very short life expectancy due to another terminal cancer and telling her story years later in apparently good health, these may bode well for quicker approvals.
Also more support for right to try especially when the treatment is so safe and side effect free, may also lead to earlier availability.
That said, there will be a ramp up in demand and with the Flaskworks technology I think additional capacity will be modularity achievable at much less costs than without.
You have to give nwbo credit for acquiring Flaskworks and it’s IP and founders at such a low cost vastly undervaluing its economic and strategic potential.
Market Data 
Markets 
AI
